News and Press Releases
CPHI Americas 2026 unveils keynote speakers tackling pharma’s toughest challenges
11 May 2026 -- Pennsylvania, US -- Informa Markets has announced its keynote speaker line-up for CPHI Americas 2026 (June 2–4), bringing together more than 80 industry thought leaders, including...
Category: Biotechnology, Other, Pharmaceutical
Posted: May 11, 2026
Scarlet Therapeutics Demonstrates In Vivo Survival of Lab-Grown Universal Red Blood Cells Equivalent to Donated Blood
£3.2M Seed Round Closed to Accelerate Platform Development 7 May 2026 -- Bristol, UK -- Scarlet Therapeutics today announces a landmark preclinical result: its proprietary cell-line derived, universal, lab-grown red...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: May 7, 2026
CARBOGEN AMCIS introduces SPRINT for early-phase development
A new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour 6 May 2026 -- Bubendorf, Switzerland -- CARBOGEN AMCIS has launched SPRINT, a dedicated approach to early-phase...
Category: BioManufacturing, Other, Pharmaceutical
Posted: May 6, 2026
CARBOGEN AMCIS Shanghai Site achieves successful outcome in Unannounced NMPA GMP Inspection
China’s NMPA confirms robust GMP compliance at CARBOGEN AMCIS Shanghai, with no observations identified following a comprehensive unannounced inspection 6 May 2026 -- Bubendorf, Switzerland -- CARBOGEN AMCIS, a Switzerland-based...
Category: BioManufacturing, Clinical Trials, Other, Pharmaceutical
Posted: May 6, 2026
Schreiner MediPharm and HERMA to Showcase Process-Reliable RFID Labeling for Vials at interpack
Blauvelt, NY, May 5, 2026 – Schreiner MediPharm, a leading developer and manufacturer of functional labels for the healthcare industry, and HERMA, an expert in labeling machines, have collaborated to...
Category:
Posted: May 5, 2026
MindMaze Therapeutics and Vibra Healthcare Announce Go-to-Market Partnership to Expand Commercial Footprint of Precision Neurotherapeutics in the U.S.
Collaboration targets large provider groups to accelerate adoption of MindMaze Therapeutics’ evidence-based neurotherapeutic platform 30 April 2026 -- Geneva, Switzerland and Pennsylvania, US -- MindMaze Therapeutics, a pioneer in advanced...
Category: Other, Pharmaceutical
Posted: April 30, 2026
U.S. FDA Grants Breakthrough Device Designation to Laguna Diagnostics’ mRNA Gene Biomarker Test to Aid in Differentiation of Schizophrenia and Bipolar I Disorder
29 April 2026 -- California, US -- Laguna Diagnostics, LLC today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the company’s mRNA Gene...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 29, 2026
NICE recommends UCB’s RYSTIGGO▼ (rozanolixizumab) for adults with antibody-positive generalised myasthenia gravis in Final Draft Guidance
Rozanolixizumab, discovered and developed in the UK, has been recommended by NICE as an add on treatment option for eligible adults with antibody-positive generalised myasthenia gravis (gMG) Recommendation represents three...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 29, 2026
Asgard Therapeutics announces oral presentation at ASGCT 2026, showcasing advanced preclinical data on AT-108 – its first-in-class, off-the-shelf, gene-based cancer immunotherapy
AT-108 induces powerful, personalized anti-cancer responses by forcing tumor cells to present their antigens to the immune system Data to be presented at ASGCT 2026 show when used as a...
Category: Biotechnology, Other, Pharmaceutical
Posted: April 27, 2026
BD and Suttons Creek Partner to Help Pharma and Biotech Companies Deliver Combination Products to Market with Confidence
The collaboration brings together consulting, device agnostic testing, and drug delivery expertise to help pharmaceutical and biotech companies reduce risk and navigate complexity for combination products, including biologics and GLP1...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: April 27, 2026
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities
Philadelphia, PA – PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of...
Category:
Posted: April 27, 2026
EMA Approves Updated Safety Information for Kite’s YESCARTA and TECARTUS Allow for a More Flexible Post-Infusion Management Approach
Update Enhances Convenience and Flexibility for Healthcare Professionals and Eligible Patients, while Maintaining CAR-T Safety Management Standards 24 April 2026 -- Stockley Park, UK -- Gilead and Kite Oncology today announced...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: April 24, 2026
Epitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian Cancer
Appoints Leading Oncologist Professor Susana Banerjee of The Royal Marsden as Chief Investigator 23 April 2026 -- Cambridge, UK and Montreal, Canada -- Epitopea, a transatlantic biotech developing off-the-shelf, durable, RNA-based cancer immunotherapies, today announced that it has received approval from the UK’s Medicines and Healthcare...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2026
Salisbury House, Station Road, Cambridge, Cambridgeshire, United Kingdom, CB1 2LA
Awen Oncology secures significant new funds to advance pioneering cancer therapeutics
23 April 2026 -- Anglesey, UK -- Awen Oncology, a pioneering Wales-based therapeutics company developing next-generation cancer treatments, has secured funds from a number of sources, worth seven figures, which...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2026
Ojemda approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration
New treatment option for rare, life-altering pediatric brain tumors Less than 10% of new medicine approvals over the past five years have focused on pediatric diseases; Ojemda (tovorafenib) represents a...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 22, 2026
